Mobilise-D: Extension Study
Study Details
Study Description
Brief Summary
The goal of this observational study is to investigate the ability of a mobility monitor to measure and predict outcomes in Parkinson's disease (PD). It is an extension of a previous study (the Mobilise-D Clinical Validation Study) and consists of an additional follow-up visit for PD participants and the recruitment of age matched control participants. The data will inform researchers about PD disease progression and normal changes in mobility associated with aging.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
This study is an extension to the Mobilise-D project which aims to develop a real world digital assessment of mobility. This Extension Study will build on the work of the Clinical Validation Study (CVS) to extend the follow-up period of the Parkinson's disease (PD) cohort and to recruit an age matched control cohort. The additional data will for allow for modelling of disease progression in PD over a longer time period and inform on progression in normal ageing.
The Mobilise-D Extension Study is an observational cohort study taking place at five clinical sites across four different countries. The study will recruit up to 551 PD participants from the CVS PD cohort and 200 age matched control participants.
The PD participants will attend a single follow-up visit 36 months after their initial CVS baseline visit. The control participants will attend a baseline visit and a 12-month follow-up visit. All study visits consist of the collection of descriptive, clinical, physical, neuropsychological data. Following each visit, participants are required to wear a body worn sensor for seven days continual monitoring.
A small sample of participants will be invited to take part in a semi-structured interview (Qualitative Sub Study) to better understand participants' experiences of PD symptoms and the impact they have on mobility. The investigators also want to know if the aspects of mobility that are being measured are relevant to people with PD. These interviews will take place face to face or remotely, depending on preference.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Control Cohort Control participants who are age- and gender-matched to the PD cohort |
|
| PD Cohort PD Patients who have completed their participation in the Mobilise-D Clinical Validation Study |
Outcome Measures
Primary Outcome Measures
- Change in LLFDI in controls [12 months]
Change in the functional component score of the Late-Life Functional Disability Index (LLFDI) in control data. This assessment has 32 items, each with a scale from 5 (no difficulty) to 1 (unable to do). Raw scores are transformed into summary scores ranging from 0 (low level in ability) to 100 (high level of ability).
- Change in LLFDI in PD [36 months]
Change in the functional component score of the Late-Life Functional Disability Index (LLFDI) in PD data. This assessment has 32 items, each with a scale from 5 (no difficulty) to 1 (unable to do). Raw scores are transformed into summary scores ranging from 0 (low level in ability) to 100 (high level of ability).
- Change in fall frequency in PD [36 months]
Change in fall frequency (in previous 6 months) in PD data
Secondary Outcome Measures
- Difference in Real Walking Speed [36 months (PD) and 12 months (control)]
Assess difference in Real Walking Speed between PD and control data as measured using a body worn sensor during a 7-day digital mobility assessment (DMA)
- Fall frequency in controls [12 months]
Change in fall frequency (in previous 6 months) in control data
- Ability of Real Walking Speed to detect change in PD severity [36 months]
Ability of Real Walking Speed (measured through digital mobility assessment) to detect change in PD disease severity as measured by the MDS Unified Parkinson's Disease Rating Scale (UPDRS). This assessment has 32 items, each with a scale from 5 (no difficulty) to 1 (unable to do). Raw scores are transformed into summary scores ranging from 0 (low level in ability) to 100 (high level of ability).
- Ability of Real Walking Speed to predict change in physical capacity [36 months (PD) and 12 months (control)]
Ability of Real Walking Speed (measured through digital mobility assessment) to detect change in physical capacity in PD and control data, as measured through the Late-Life Functional Disability Index (LLFDI). This assessment has 32 items, each with a scale from 5 (no difficulty) to 1 (unable to do). Raw scores are transformed into summary scores ranging from 0 (low level in ability) to 100 (high level of ability).
- Ability of Real Walking Speed to predict change in PD severity [36 months]
Ability of Real Walking Speed (measured through digital mobility assessment) to predict change in PD disease severity as measured by the MDS Unified Parkinson's Disease Rating Scale (UPDRS). This assessment has 32 items, each with a scale from 5 (no difficulty) to 1 (unable to do). Raw scores are transformed into summary scores ranging from 0 (low level in ability) to 100 (high level of ability).
Eligibility Criteria
Criteria
Control Cohort:
Inclusion Criteria:
-
Aged 50 years or over
-
Able to walk 4 meters independently without walking aids
-
Anticipated availability for 12 months.
-
Ability to consent and comply with any study specific procedures.
-
Willingness to wear a wearable sensor for mobility monitoring
-
Able to read and write in first language in the respective country
Exclusion Criteria:
-
Occurrence of any of the following within 3 months prior to informed consent: myocardial infarction, hospitalization for unstable angina, stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), implantation of a cardiac resynchronization therapy device (CRTD), active treatment for cancer or other malignant disease, uncontrolled congestive heart disease (NYHA class >3), acute psychosis or major psychiatric disorders or continued substance abuse, other neurological or orthopaedic impairment that significantly impacts on gait
-
Patients with a clinical diagnosis of PD, COPD, proximal hip fracture or MS
-
History of dementia/significant cognitive impairment, or movement disorder (including essential tremor)
PD Cohort
Inclusion Criteria:
- Participant in the Mobilise-D Clinical Validation Study (CVS) PD Cohort - see below.
CVS PD Cohort:
Inclusion criteria:
-
Aged 18 or over
-
Patients with the clinical diagnosis of PD according to the recent criteria of the Movement Disorder Society
-
Hoehn & Yahr stage I-III
Exclusion Criteria:
-
History consistent with Dementia with Lewy Bodies (DLB), atypical parkinsonian syndromes (including multiple system atrophy or progressive supranuclear palsy, diagnosed according to accepted criteria)
-
Repeated strokes or stepwise progression of symptoms, leading to a diagnosis of 'vascular parkinsonism'
-
Drug-induced Parkinsonism
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Newcastle-upon-Tyne Hospitals NHS Trust
- KU Leuven
- University of Kiel
- University Hospital Erlangen
- Tel-Aviv Sourasky Medical Center
- University College Dublin
Investigators
- Principal Investigator: Alison Yarnall, PhD, Newcastle University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 10402
- MJFF-022735
- MJFF-022736
- 323855